Abstract：
UNASSIGNED: Our study aimed to compare the outcomes of COVID-19 patients who met a low-risk inclusion criteria for veno-venous extra corporeal membrane oxygenation (VV ECMO) with those who did not meet criteria due to higher risk but were subsequently cannulated.
UNASSIGNED: This was a retrospective observational cohort study that included adult patients who were placed on VV ECMO for COVID-19 related acute respiratory distress syndrome (ARDS) at a tertiary care academic medical center. The primary outcome was the association between the low-risk criteria and mortality. The patients met the criteria if they met EOLIA severe ARDS criteria, no absolute contraindications (age > 60 years, BMI > 55 kg/m2, mechanical ventilation (MV) duration >7 days, irreversible neurologic damage, chronic lung disease, active malignancy, or advanced multiorgan dysfunction), and had three or less relative contraindications (age > 50 years, BMI > 45 kg/m2, comorbidities, MV duration > 4 days, acute kidney injury, receiving vasopressors, hospital LOS > 14 days, or COVID-19 diagnosis > 4 weeks).
UNASSIGNED: Sixty-five patients were included from March 2020 through March 2022. Patients were stratified into low-risk or high-risk categories. The median Sequential Organ Failure Assessment score was 7 and the median PaO2/FiO2 ratio was 44 at the time of ECMO cannulation. The in-hospital mortality was 47.8% in the low-risk group and 69.0% in the high-risk group (p = 0.096).
UNASSIGNED: There was not a statistically significant difference in survival between low-risk patients and high-risk patients; however, there was a trend toward higher survival in the lower-risk group.
UNASSIGNED: This was a retrospective observational cohort study that included adult patients who were placed on VV ECMO for COVID-19 related acute respiratory distress syndrome (ARDS) at a tertiary care academic medical center. The primary outcome was the association between the low-risk criteria and mortality. The patients met the criteria if they met EOLIA severe ARDS criteria, no absolute contraindications (age > 60 years, BMI > 55 kg/m2, mechanical ventilation (MV) duration >7 days, irreversible neurologic damage, chronic lung disease, active malignancy, or advanced multiorgan dysfunction), and had three or less relative contraindications (age > 50 years, BMI > 45 kg/m2, comorbidities, MV duration > 4 days, acute kidney injury, receiving vasopressors, hospital LOS > 14 days, or COVID-19 diagnosis > 4 weeks).
UNASSIGNED: Sixty-five patients were included from March 2020 through March 2022. Patients were stratified into low-risk or high-risk categories. The median Sequential Organ Failure Assessment score was 7 and the median PaO2/FiO2 ratio was 44 at the time of ECMO cannulation. The in-hospital mortality was 47.8% in the low-risk group and 69.0% in the high-risk group (p = 0.096).
UNASSIGNED: There was not a statistically significant difference in survival between low-risk patients and high-risk patients; however, there was a trend toward higher survival in the lower-risk group.
摘要：
■我们的研究旨在比较符合静脉-静脉体外膜氧合（VVECMO）低风险纳入标准的COVID-19患者与因风险较高而不符合标准但随后被插管的患者的结局。
这是一项回顾性观察性队列研究，包括在三级护理学术医疗中心因COVID-19相关急性呼吸窘迫综合征（ARDS）接受VVECMO治疗的成年患者。主要结果是低风险标准和死亡率之间的关联。如果患者符合EOLIA严重ARDS标准，无绝对禁忌症(年龄>60岁,BMI>55kg/m2，机械通气（MV）持续时间>7天，不可逆的神经损伤,慢性肺病,活动性恶性肿瘤，或晚期多器官功能障碍)，并且有三个或更少的相对禁忌症（年龄>50岁，BMI>45kg/m2，合并症，MV持续时间>4天，急性肾损伤，接受血管加压药,医院LOS>14天，或COVID-19诊断>4周）。
■从2020年3月至2022年3月纳入65名患者。将患者分为低风险或高风险类别。在ECMO插管时，序贯器官衰竭评估评分中位数为7，PaO2/FiO2比值中位数为44。低危组的住院死亡率为47.8%，高危组为69.0%（p=0.096）。
■低风险患者和高风险患者之间的生存率差异无统计学意义；然而，低风险组的生存率有较高的趋势.
这是一项回顾性观察性队列研究，包括在三级护理学术医疗中心因COVID-19相关急性呼吸窘迫综合征（ARDS）接受VVECMO治疗的成年患者。主要结果是低风险标准和死亡率之间的关联。如果患者符合EOLIA严重ARDS标准，无绝对禁忌症(年龄>60岁,BMI>55kg/m2，机械通气（MV）持续时间>7天，不可逆的神经损伤,慢性肺病,活动性恶性肿瘤，或晚期多器官功能障碍)，并且有三个或更少的相对禁忌症（年龄>50岁，BMI>45kg/m2，合并症，MV持续时间>4天，急性肾损伤，接受血管加压药,医院LOS>14天，或COVID-19诊断>4周）。
■从2020年3月至2022年3月纳入65名患者。将患者分为低风险或高风险类别。在ECMO插管时，序贯器官衰竭评估评分中位数为7，PaO2/FiO2比值中位数为44。低危组的住院死亡率为47.8%，高危组为69.0%（p=0.096）。
■低风险患者和高风险患者之间的生存率差异无统计学意义；然而，低风险组的生存率有较高的趋势.
